These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29420662)

  • 1. Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.
    Borek A; Sokolowska-Wedzina A; Chodaczek G; Otlewski J
    PLoS One; 2018; 13(2):e0192194. PubMed ID: 29420662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.
    Sokolowska-Wedzina A; Chodaczek G; Chudzian J; Borek A; Zakrzewska M; Otlewski J
    Mol Cancer Res; 2017 Aug; 15(8):1040-1050. PubMed ID: 28483948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.
    Chudzian J; Szlachcic A; Zakrzewska M; Czub M; Pustula M; Holak TA; Otlewski J
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
    Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
    Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study.
    Jalilzadeh-Razin S; Mantegi M; Tohidkia MR; Pazhang Y; Pourseif MM; Barar J; Omidi Y
    Daru; 2019 Jun; 27(1):21-34. PubMed ID: 30607886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
    Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
    Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
    Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE
    J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.
    Ten Haaf A; Pscherer S; Fries K; Barth S; Gattenlöhner S; Tur MK
    Immunol Lett; 2015 Aug; 166(2):65-78. PubMed ID: 26045318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
    Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
    Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology.
    Tohidkia MR; Asadi F; Barar J; Omidi Y
    BioDrugs; 2013 Feb; 27(1):55-67. PubMed ID: 23344946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor.
    Nickho H; Younesi V; Aghebati-Maleki L; Motallebnezhad M; Majidi Zolbanin J; Movassagh Pour A; Yousefi M
    Bioengineered; 2017 Sep; 8(5):501-510. PubMed ID: 27849134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
    [No Abstract]   [Full Text] [Related]  

  • 16. Reformatting of scFv antibodies into the scFv-Fc format and their downstream purification.
    Bujak E; Matasci M; Neri D; Wulhfard S
    Methods Mol Biol; 2014; 1131():315-34. PubMed ID: 24515475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization.
    Schneider KT; Kirmann T; Wenzel EV; Grosch JH; Polten S; Meier D; Becker M; Matejtschuk P; Hust M; Russo G; Dübel S
    Front Cell Infect Microbiol; 2021; 11():717689. PubMed ID: 34869052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
    Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
    Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.